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Abstract
Background: The regular increase in the incidence of respiratory illness caused by respiratory
syncytial virus (RSV) during winter months in the United Kingdom, and other countries with
temperate climate is usually accompanied by increased bed pressures especially in paediatric units
in these countries. As a result, there is usually an increase in the demand for infection control
services during these months. This makes obvious the need for making a rapid diagnosis of the
infection during these months. BINAX NOW RSV (Maine, USA), a rapid membrane based
immunochromatographic assay was designed to achieve this objective.
Methods: This study evaluated the diagnostic performance of BINAX NOW RSV in comparison
with the methods routinely used in our laboratory namely direct immunofluorescence (DIF) and
cell culture.
Results and conclusion: Results indicate that Binax Now RSV could be relied on to make
infection control decisions in paediatric units during periods of peak RSV activity.
Background
Respiratory syncytial virus (RSV) is the most common
cause of bronchiolitis and pneumonia among infants and
children under 1 year of age. In temperate climates, RSV
infections usually occur during annual community out-
breaks, often lasting 4 to 6 months, during the late fall,
winter, or early spring months. The timing and severity of
outbreaks in a community vary from year to year. RSV
spreads efficiently among children during the annual out-
breaks, and most children will have serologic evidence of
RSV infection by 2 years of age[1].
Virus isolation is considered the 'gold standard' method
of RSV diagnosis. However it is cumbersome and may also
require up to a week to produce a result. The shell vial
method which essentially involves centrifugation of the
specimen directly onto the cell monolayer at 700 g for 1
hour may reduce this time considerably to about 24
hours[2,3]. For optimal recovery of the virus by cell cul-
ture, it is essential that specimen be transported to the lab-
oratory at refrigerator temperature (4°C) or on wet ice[4].
If it is anticipated that samples may take longer than 24
hours between collection and cell inoculation then the
specimen should be rapidly frozen to -70°C to maintain
viable viral titre[4]. A combination of human epithelial
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cell lines, primary monkey kidney cell lines and human
fibroblasts is necessary for optimal recovery of the
virus[4].
Direct Immunofluorescence (DIF) is a quicker method of
achieving RSV antigen detection in respiratory specimens,
making it possible to have a result a few hours after spec-
imen collection. However it is a subjective test and could
give false positive results[5]. Furthermore, it is a labour
intensive technique, takes longer to perform than the
rapid test and requires well trained, experienced technol-
ogists for correct interpretation of results.
NOW RSV (Binax, Maine USA) is a rapid membrane based
immunochromatographic assay which is FDA approved
for the qualitative detection of RSV fusion proteins in
nasal wash and nasopharyngeal specimens from sympto-
matic children less than 5 years of age[6]. The test takes 15
minutes to perform.
Using this test method a result could be achieved within 2
hours or less of specimen collection.
The current testing protocol in our laboratory for the diag-
nosis of respiratory viral infection is to carry out DIF and
cell culture on all nasopharyngeal aspirates and broncho-
alveolar lavages. During the winter months when the inci-
dence of RSV infection increases, it becomes necessary to
rapidly make a diagnosis for prompt institution of infec-
tion control measures especially in paediatric wards to
limit the spread of the infection. NOW RSV appears to be
promising in achieving this objective.
Objective
The aim of this study was to assess the diagnostic perform-
ance of NOW RSV in comparison with tissue culture and
DIF.
Materials and methods
100 (one hundred) specimens consisting of 91 nasopha-
ryngeal aspirates (NPA) and 9 broncho-alveolar lavages
(BAL) received in the virus isolation unit of the West Mid-
lands Public Health Laboratory (Health Protection
Agency), Birmingham Heartlands Hospital between Octo-
ber and December 2003 were tested in parallel by Now
RSV, DIF and cell culture for evidence of RSV infection. All
the BAL specimens were from adult patients (age range 19
– 69 years). 53 NPAs were from infants <5 months old, 27
from children aged 5 months to 5 years and 11 from older
children and adults (age range 13 – 52 years).
NOW RSV
Binax NOW RSV is a rapid membrane based immuno-
chromatographic technique which is designed to detect
RSV fusion protein antigen in nasal washes and nasopha-
ryngeal swab specimens. The test utilises anti RSV anti-
body conjugated to visualising particles and adsorbed
onto a nitrocellulose membrane to form the 'sample line'.
Performing the test involves a one step technique of add-
ing the sample to the white pad at the top of the test strip,
and incubating for 15 minutes. There is no need for any
special laboratory equipment, and no need for any special
incubation conditions. The specimens were tested, and
results read according to the manufacturer's instruction
[6].
Virus isolation
About 1 ml of the specimen was added to 2 ml of Virus
Transport Medium (VTM) and mixed. VTM contains a salt
solution to ensure proper ionic concentration, a buffer to
maintain ph, a source of protein for viral particle stability,
antibiotics and antifungal to prevent bacterial and fungal
overgrowth [7]. A few drops were then inoculated into
healthy monolayers of MRC5, RMK and PLC (Primary
liver carcinoma) cell lines (ECACC Porton Down UK).
Inoculated tubes were incubated in rotary drums at 33°C
and examined twice a week for cytopathological effect
(CPE). When a significant CPE was detected, the culture
medium was discarded leaving a few drops into which the
cells on the culture tube were scrapped. The suspended
cells were spotted onto teflon coated slides previously
cleaned with alcohol and treated as for DIF (see below).
Specimens that showed no CPE after 7 days of incubation
were subjected to haemadsorption. Immunofluorescence
was carried out on positive haemadsorbing specimens.
Specimens which gave a negative reaction to haemadsorp-
tion were incubated for a further 7 days. Specimens which
showed no CPE after 2 weeks of incubation were dis-
carded and reported as negative after a negative haemad-
sorption test.
Direct immunofluorescence
Specimens in the universal container were centrifuged at
low speed for 10 minutes. The supernatant was discarded
and 10 mls of PBS (phosphate buffered saline) was added
to the deposit, mixed well and re-centrifuged at the same
speed. A third centrifugation step was done if the original
specimen contained a lot of mucus. After discarding the
supernatant, the cell deposit was re-suspended in a few
drops of PBS and spotted onto teflon coated slides previ-
ously cleaned with alcohol, allowed to dry, fixed in ace-
tone for 10 minutes and stained with anti RSV
monoclonal antibody conjugated with fluorescein isothi-
ocyanate (FITC) (IMAGEN DAKO, Cambridgeshire UK).
Slides were incubated at 37°C for 30 minutes in a humid
chamber, rinsed, and washed in PBS for 5 minutes. Slides
were then drained dry, mounted with a cover slip using
mounting fluid (IMAGEN, DAKO Cambridgeshire, UK)
and examined by fluorescent microscope.Annals of Clinical Microbiology and Antimicrobials 2006, 5:13 http://www.ann-clinmicrob.com/content/5/1/13
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A sample was considered true positive if it was a) positive
by cell culture or b) positive by DIF and NOW RSV, if cul-
ture is negative. A true negative result was defined as a neg-
ative result obtained by cell culture, and at least one of the
other two methods.
Results
11 out of the 100 specimens (11%) were positive for RSV
by cell culture, 23% (23 out of 100) were positive by DIF
while 15% (15 out of 100) were positive by NOW RSV
(Table 1). 19% (19 out of 100) were considered true pos-
itives – 11 positive by cell culture and 8 positive by both
NOW RSV and DIF. 81% (81 out of 100) were negative by
culture and at least one other method (true negatives). 7
specimens were positive by all three methods.
Using the above definitions of true positive and true neg-
ative respectively, the sensitivity and specificity of NOW
RSV, DIF and cell culture respectively were 15/19(78.9%)
and 81/81(100%); 19/19(100%) and 77/81(95.1%); 11/
19(58.9%) and 81/81(100%).
Out of the 91 NPAs 75 were negative either by cell culture
or by both NOW RSV and DIF, (true negatives), 16 were
positive either by cell culture or by the other two methods
(true positives). 14 of these true positive specimens were
positive by NOW RSV giving a sensitivity of 87.5%. All 75
true negative specimens were negative by NOW RSV giv-
ing a specificity of 100%. Similarly, DIF and cell culture
had sensitivity and specificity respectively of 100%(16/
16) and 94.7%(71/75); and 43.8%(7/16) and 100%(75/
75) respectively.
Of the 9 BAL specimens, 6 were negative by all three test
methods, 1 was positive by all three methods, and 2 were
positive by DIF and cell culture, and negative by NOW
RSV. Thus sensitivities and specificities for NOW RSV, DIF
and cell culture were 33.3% (1/3) and 100% (6/6); 100%
(3/3) and 100% (6/6); 100% (3/3) and 100% (6/6)
respectively (table 3). One of the 6 negative BAL speci-
mens was found positive for HSV 1 by DIF and cell cul-
ture.
All 11 NPAs from older children and adult (13 – 52 years)
were negative for RSV by all three test methods. 5 of these
specimens were found positive for influenza A virus by
DIF and cell culture.
Of the 27 NPAs from children aged 5 months to 5 years,
20 were negative by all three test methods, 2 were positive
by all three methods, 2 were positive by NOW RSV and
DIF, while 3 were positive by only DIF. Thus sensitivities
and specificities in this age group for NOW RSV, DIF and
cell culture were 100% (4/4) and 100% (23/23); 100%
(4/4) and 87% (20/23) and 50% (2/4) and 100% (23/23)
respectively (table 3). 7 out of the 23 true negative speci-
mens were found positive for influenza A by DIF and cell
culture.
Out of the 53 NPAs from infants aged less than 5 months,
12 were positive by either cell culture or NOW RSV and
DIF (true positives) and 41 were negative by cell culture
and at least one other method (true negatives). 1 speci-
men was positive by DIF but negative by NOW RSV and
cell culture. 10 out of the 12 true positive specimens were
positive by NOW RSV, and all 41 true negative specimens
were found negative by that test method. All 12 true pos-
itive specimens were found positive by DIF while 40 out
of the 41 true negative specimens were found negative by
DIF. 6 out of the 12 true positive specimens were found
positive by cell culture, and all 41 true negative specimens
were found negative by cell culture. Thus sensitivities and
specificities for NOW RSV, DIF and cell culture were 83%
(10/12) and 100% (41/41); 100% (12/12) and 97.6%
(40/41); 50% (6/12) and 100% (41/41) respectively
(Table 2). 5 out of the negative specimens in this group
were positive for influenza A by DIF and cell culture, 1
specimen was positive for parainfluenza virus 1 and 2
were positive for parainfluenza virus 2. The specimen
which gave a positive result for RSV by DIF only was also
found positive for enterovirus (untyped) by cell culture.
A summary of the three test methods performance on the
different specimens tested is presented in Table 3.
Discussion
The ease of performance and the rapidity of result report-
ing make NOW RSV test method a very useful tool espe-
cially in the winter months when the incidence of RSV
infection rises. This is especially useful in making deci-
sions on instituting infection control measures in paediat-
ric units. The high specificity of this test method indicates
that it could be relied on in making such decisions. The
reduced sensitivity of 78.9% (overall) or 87.5% (NPAs)
found in this study re-echoes the manufacturer's warning
Table 1: Overall results by BINAX NOW RSV, DIF and cell culture
NOW RSV DIF CELL CULTURE
POSITIVE 15 23 11
NEGATIVE 85 77 89
TOTAL 100 100 100Annals of Clinical Microbiology and Antimicrobials 2006, 5:13 http://www.ann-clinmicrob.com/content/5/1/13
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on limitations of the assay. It is recommended that a neg-
ative specimen be tested by another sensitive rapid
method like direct immunofluorescence to improve sensi-
tivity.
In a similar evaluation conducted by Mackie PL et al[8],
on the use of NOW RSV as a point of care test (POCT) for
the diagnosis of RSV, sensitivity and specificity values of
87% and 94% respectively were obtained when compared
to direct immunofluorescence alone. These values
increased to 92% and 94% respectively when discrepant
results were re-tested by laboratory personnel according to
the manufacturer's instructions. In this study, using the
three test methods of NOW RSV, DIF and virus isolation,
and defining a true positive as a positive result obtained
by cell culture or both NOW RSV and DIF if culture is neg-
ative; and a true negative as a negative result obtained by
cell culture and at least one other method; DIF correctly
identified all the positive samples but also had the highest
number of false positive results. On the other hand all the
samples identified as positive by NOW RSV were true pos-
itives. 4 samples (overall) or 2 samples (NPAs) found neg-
ative by NOW RSV were actually positive. Low viral load
in such specimens may possibly account for the false neg-
ative results obtained [6].
The relatively poor performance of virus isolation in terms
of sensitivity may be explained at least in part by non-via-
bility of Viral particles in the specimens, when they were
received in the laboratory. Virus isolation was the only test
method out of the three that required the presence of via-
ble viral particles to achieve a positive result. A significant
number of these specimens were from hospitals or labora-
tories located in different cities from our laboratory, and
some of these specimens were not received in the labora-
tory until the following day. Furthermore, these speci-
mens were not transported to the laboratory at optimal
temperatures (none of these samples were shipped in cold
boxes or on ice packs). Considerable delay was also noted
from the time of sample collection from in patients at the
Birmingham Heartlands Hospital and reception at our
laboratory where the specimens were tested. Further delay
may possibly have occurred from the time specimen was
received at the central specimen processing unit to when
the specimen actually got to the virus isolation laboratory.
The poor performance of NOW RSV on BAL specimens
compared to DIF and cell culture may be worthy of note.
However final conclusions can not be drawn from this
study as the number of samples tested was small. In a sim-
ilar study conducted by Ohm-Smith et al[5], sensitivity
and specificity values found for DIF and NOW RSV were
Table 3: Summary of the test performance of the three methods.
SPECIMEN TYPE TEST METHOD TEST PERFORMANCE
Sensitivity (%) Specificity (%) PPV* (%) NPV+ (%)
NPA <5 months (n = 
53)
NOW RSV 10/12 (83) 41/41 (100) 100 95.35
DIF 12/12 (100) 40/41 (97.6) 92.31 100
CELL CULTURE 6/12 (50) 41/41 (100) 100 87.23
NPA 5 months – 5 
years (n = 27)
NOW RSV 4/4 (100) 23/23 (100) 100 100
DIF 4/4 (100) 20/23 (87) 57.14 100
CELL CULTURE 4/4 (50) 23/23 (100) 100 92
BAL Adults (n = 9) NOW RSV 1/3 (33.3) 6/6 (100) 100 75
DIF 3/3 (100) 6/6 (100) 100 100
CELL CULTURE 3/3 (100) 6/6 (100) 100 100
*PPV = Positive predictive value
+NPV = Negative predictive value
Table 2: Test performance on 53 NPAs from patients less than 5 months old.
NOW RSV DIF CELL CULTURE
TRUE POSITIVE 10 12 6
FALSE POSITIVE 0 1 0
TRUE NEGATIVE 41 40 41
FALSE NEGATIVE 2 0 6
TOTAL 53 53 53
SENSITIVITY (%) 83 100 50
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93% and 97%; 89% and 100% respectively, using cell cul-
ture as the gold standard. A reduced sensitivity of NOW
RSV on respiratory samples from adults was demonstrated
by their findings. Their tests were conducted on fresh sam-
ples only. In this study, none of the 11 nasopharyngeal
specimens tested from older children (>13 years) and
adults gave a positive result by any of the three test meth-
ods. This finding is in consonance with the fact that
immunity to RSV is usually acquired early in life [1].
About half of the specimens in this age group were found
positive for influenza A virus, indicating that influenza A
virus remains the leading cause of respiratory disease in
adulthood during winter.
Conclusion and recommendation
The absolute specificity of NOW RSV found in this study
indicates that this rapid test method could be relied on to
make infection control decisions during periods of peak
RSV activity. The need to adhere to the manufacturer's
advice to subject samples which give negative results to
another test method is also being emphasized. Virus iso-
lation might probably retain it's position as the final arbi-
ter in RSV diagnosis not only because of it's absolute
specificity as indicated in this study but also because it
remains the only test method that makes available viable
viral particles for further laboratory studies.
Finally, it could be said from the results of this evaluation
study, that the combination NOW RSV and DIF is likely to
yield reliable results in the rapid diagnosis of respiratory
infections caused by RSV.
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